Genzyme, a Sanofi Company, has appointed Brendan Martin as its new general manager for UK and Ireland.

Brendan will be responsible for all Genzyme’s commercial activities in the UK and Ireland and will report to Robin Kenselaar, head of Genzyme’s EMEA region.

Brendan joined Genzyme in 2002 and was responsible for establishing and developing Genzyme’s lysosomal storage disorders business in Ireland.

In 2007, he became business unit director and in 2010, deputy general manager for UK and Ireland.

He will be leading Genzyme in the UK and Ireland which will now, as part of the Sanofi group, focus on rare inherited diseases and immune diseases.

Brendan’s appointment follows the decision of Paul Drohan, senior VP and general manager UK and Ireland, to leave Genzyme following a 17-year career with the company.

Robin Kenselaar, Head of Genzyme EMEA said: “Brendan’s appointment as general manager UK and Ireland comes at a key time for the business as it builds its multiple sclerosis franchise and continues to develop in rare diseases.

“In addition to welcoming Brendan to his new role, I take this opportunity to thank Paul Drohan for his significant contribution to Genzyme in his most recent roles in Europe and the Commonwealth and also in originally developing Genzyme’s Canadian organisation from a two-person start up to a successful business.”